Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;5(3):313-27.
doi: 10.1007/s40121-016-0116-z. Epub 2016 Jul 7.

Hepatitis C Therapy in Renal Patients: Who, How, When?

Corinne Isnard Bagnis  1   2 , Patrice Cacoub  3   4   5   6
Affiliations
Review

Hepatitis C Therapy in Renal Patients: Who, How, When?

Corinne Isnard Bagnis et al. Infect Dis Ther. 2016 Sep.

Abstract

Renal patients are overexposed to hepatitis C virus (HCV) infection. Hepatitis C virus infection may induce renal disease, i.e., cryoglobulinemic membrano-proliferative glomerulopathy and non-cryoglobulinemic nephropathy. Hepatitis C virus impacts general outcomes in chronic kidney disease, dialysis or transplanted patients. Hepatitis C virus infection is now about to be only part of their medical history thanks to new direct acting antiviral drugs exhibiting as much as over 95% of sustained virological response. All HCV-infected patients potentially can receive the treatment. Control of the virus is associated with better outcomes in all cases, whatever the severity of the hepatic or renal disease. This article focuses on HCV-induced renal diseases, the reciprocal impact of HCV infection on the renal outcome and renal status in liver disease, use of new direct-acting antiviral drugs with dosage adaptations and the most recent safety data.

Keywords: Chronic kidney disease; Cryoglobulinemia; Dialysis; Direct acting antiviral agents; Hepatitis C; Membranoproliferative glomerulonephritis; Sustained virological response; Transplantation.

PubMed Disclaimer

References

    1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362. doi: 10.1126/science.2523562. - DOI - PubMed
    1. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum. 1999;42(10):2204–2212. doi: 10.1002/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D. - DOI - PubMed
    1. Cacoub P, Gragnani L, Commarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165–S173. doi: 10.1016/j.dld.2014.10.005. - DOI - PubMed
    1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107–115. doi: 10.1111/j.1469-0691.2010.03432.x. - DOI - PubMed
    1. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335–2342. doi: 10.1111/j.1523-1755.2004.00649.x. - DOI - PubMed

LinkOut - more resources